The companies plan to pair their pump system with the Abbott dual glucose-ketone sensor, currently under development. Ypsomed and CamDiab join three other companies set to pair their pumps with the sensor after Abbott recently agreed to implement integrations with automated insulin delivery systems offered by Sequel Med Tech, Tandem Diabetes Care and Beta Bionics,
According to a news release, the planned integration can enhance the capabilities of the mylife Loop. It enables people to garner real-time access to both glucose and ketone levels through a single wearable sensor. The enhanced functionality supports more informed diabetes management, especially for those with type 1 at risk of diabetic ketoacidosis (DKA).
mylife Loop combines the adaptive mylife CamAPS FX app, the mylife YpsoPump insulin pump and a CGM sensor. It currently pairs with the FreeStyle Libre 3 or FreeStyle Libre 3 Plus from Abbott and the Dexcom G6. The companies market the offering in most European countries, Canada, Australia and New Zealand. They recently announced an expanded rollout for the system with an app for the iPhone.
Once Abbott earns regulatory approval, the companies expect to make the new integrated solution available in select markets.
“We are excited to collaborate with Abbott on this important innovation,” said said Roman Hovorka, director of CamDiab. “By incorporating future ketone monitoring alongside glucose data with the mylife CamAPS FX app, we are taking a major step forward in delivering a closed-loop solution that is designed to enhance safety and reduces burden for people – and their loved ones living with type 1 diabetes.”
